<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312462265</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312462265</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Mavrogeni</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462265">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203312462265"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bratis</surname><given-names>K</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462265">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Markussis</surname><given-names>V</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462265">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Spargias</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462265">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Papadopoulou</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462265">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Papamentzelopoulos</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462265">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Constadoulakis</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312462265">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Matsoukas</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312462265">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kyrou</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312462265">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kolovou</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462265">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312462265"><label>1</label>Onassis Cardiac Surgery Center, Athens, Greece</aff>
<aff id="aff2-0961203312462265"><label>2</label>Locus Medicus Lab, Athens, Greece</aff>
<aff id="aff3-0961203312462265"><label>3</label>Bioiatriki MRI Unit, Athens, Greece</aff>
<author-notes>
<corresp id="corresp1-0961203312462265">Correspondence to: Sophie Mavrogeni, 50 Esperou Street, 175-61 P. Faliro, Athens, Greece. Email: <email>soma13@otenet.gr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>1</issue>
<fpage>34</fpage>
<lpage>43</lpage>
<history>
<date date-type="received"><day>19</day><month>2</month><year>2012</year></date>
<date date-type="accepted"><day>31</day><month>7</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec01-0961203312462265"><title>Objective</title>
<p>The objective of this paper is to evaluate the diagnostic role of cardiac magnetic resonance imaging (CMR) in detecting myocardial inflammation in systemic lupus erythematosus (SLE) and its differentiation from viral myocarditis.</p>
</sec>
<sec id="sec02-0961203312462265" sec-type="subjects"><title>Patients and methods</title>
<p>Fifty patients with suspected infective myocarditis (IM), with chest pain, dyspnoea or altered ECG, increase in troponin I and/or NT-pro BNP, with or without a history of flu-like syndrome or gastroenteritis and elevated C-reactive protein (CRP) within three to five (median four) weeks before admission, 25 active SLE patients, aged 38 ± 3 years, and 20 age-matched controls were prospectively evaluated by clinical assessment, ECG, echocardiogram and CMR. All patients underwent coronary angiography, and those with significant coronary artery disease (CAD) were excluded. CMR was performed using STIR T2-W (T2W), early T1-W (EGE) and late T1-W (LGE). Endomyocardial biopsies were performed when clinically indicated by current guidelines. Specimens were examined by immunohistological and polymerase chain reaction (PCR) analysis.</p>
</sec>
<sec id="sec03-0961203312462265" sec-type="results"><title>Results</title>
<p>Positive coronary angiography for CAD excluded 10/50 suspected IM and 5/25 active SLE. Positive clinical criteria for acute myocarditis were fulfilled by 28/40 suspected IM and only 5/20 active SLE. CMR was positive for myocarditis in 35/40 suspected IM and in 16/20 active SLE. Endomyocardial biopsy (EMB), performed in 25/35 suspected IM and 7/16 active SLE with positive CMR, showed positive immunohistology in 18/25 suspected IM and 3/7 active SLE. Infectious genomes were identified in 24/25 suspected IM and 1/7 active SLE.</p>
</sec>
<sec id="sec04-0961203312462265" sec-type="conclusions"><title>Conclusions</title>
<p>CMR-positive IM patients were more symptomatic than active SLE. More than half of CMR-positive patients also had positive EMB. PCR was positive in almost all IM, but unusual in SLE. Due to the subclinical presentation of SLE myocarditis and the limitations of EMB, CMR presents the best alternative for the diagnosis of SLE myocarditis.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Infective myocarditis</kwd>
<kwd>viruses</kwd>
<kwd>endomyocardial biopsy</kwd>
<kwd>polymerase chain reaction</kwd>
<kwd>coronary artery disease</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>cardiac magnetic resonance</kwd>
<kwd>coronary angiography</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312462265" sec-type="intro"><title>Introduction</title>
<p>Myocardial inflammation can be due to infectious, toxic, or autoimmune factors. Although infective myocarditis (IM) remains the clinical routine for cardiologists, autoimmune diseases presented with myocardial inflammation, like systemic lupus erythematosus (SLE), should also be considered. The clinical presentation of myocarditis, independently of causative factors, ranges from non-specific systemic symptoms to sudden death.<sup><xref ref-type="bibr" rid="bibr1-0961203312462265">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203312462265">2</xref></sup> According to recent data, the prevalence of IM myocarditis was found to be up to 42% of unexplained deaths in people aged 35 years or younger,<sup><xref ref-type="bibr" rid="bibr3-0961203312462265">3</xref></sup> and it was documented as a cause of dilated cardiomyopathy in 5–10% of patients in large prospective series.<sup><xref ref-type="bibr" rid="bibr4-0961203312462265">4</xref>,<xref ref-type="bibr" rid="bibr5-0961203312462265">5</xref></sup> The clinical detection of SLE myocarditis ranges from 3% to 15%, although its frequency in autopsy studies is higher, suggesting the subclinical presentation of the disease.<sup><xref ref-type="bibr" rid="bibr6-0961203312462265">6</xref>,<xref ref-type="bibr" rid="bibr7-0961203312462265">7</xref></sup> Furthermore, the detection of myocarditis in SLE demands an aggressive treatment to avoid acute and/or chronic complications.<sup><xref ref-type="bibr" rid="bibr6-0961203312462265">6</xref></sup> The early diagnosis of myocarditis, independently of causative factors, is of great importance due to its wide variety of presentation, the lack of standardized diagnostic process and the differences in therapeutic protocols that should be followed in each case.</p>
<p>Cardiac magnetic resonance (CMR) is a promising tool for diagnosing myocarditis because of its ability to detect early subtle tissue changes both in subclinical and clinically overt cases.<sup><xref ref-type="bibr" rid="bibr7-0961203312462265">7</xref></sup> According to recent data from the EuroCMR registry, myocarditis was the most common indication for CMR.<sup><xref ref-type="bibr" rid="bibr8-0961203312462265">8</xref></sup> However, CMR findings need further validation against clinical criteria and endomyocardial biopsy (EMB). According to our knowledge, the only known combination of CMR and EMB data in Europe was a reference to infective myocarditis in a German and a Greek population.<sup><xref ref-type="bibr" rid="bibr9-0961203312462265">9</xref>,<xref ref-type="bibr" rid="bibr10-0961203312462265">10</xref></sup></p>
<p>The aim of our study was to evaluate the diagnostic role of CMR in detecting myocardial inflammation in SLE and its differentiation from viral myocarditis, comparing the expanded clinical criteria, the CMR and the EMB data of these patients.</p>
</sec>
<sec id="sec2-0961203312462265" sec-type="subjects"><title>Patients and methods</title>
<sec id="sec3-0961203312462265" sec-type="subjects"><title>Patient population</title>
<p>In this study, 50 (30 men (M)/20 women (W)) consecutive patients suspected of having IM and 25 (5 M/20 W) patients with active SLE (European Consensus Lupus Activity Measurement (ECLAM) &gt;5, mean 18, range 8–30), aged 38 ± 8 years, were recruited in an inpatient setting and were prospectively evaluated by clinical assessment, electrocardiogram (ECG), echocardiogram and CMR. Twenty age-matched volunteers without any history of cardiac or systemic disease served as controls. All patients underwent coronary angiography as a prerequisite to be included in the study. Those with coronary artery stenosis &gt;70% were excluded from analysis. EMB was performed when clinically indicated by current clinical guidelines for myocarditis management.<sup><xref ref-type="bibr" rid="bibr11-0961203312462265">11</xref></sup></p>
<p>The inclusion criteria for IM were based on a combination of chest pain, dyspnoea or altered ECG, increase in troponin I and/or N-terminal fragment pro-B-type natriuretic peptide (NT-pro BNP), with or without a history of flu-like syndrome or gastroenteritis and elevated C-reactive protein (CRP) within three to five (median four) weeks before admission, and without evidence of coronary artery disease (CAD) or spasm defined by catheterization. Exclusion criteria for IM were: the presence of CAD or spasm, the general contraindications to CMR and the presence of abnormal renal function.</p>
<p>The inclusion criteria for SLE were the presence of active disease with evidence of possible heart involvement from clinical history, symptoms, physical examination, ECG, laboratory findings and routine echocardiogram. SLE diagnosis followed the American College of Rheumatology (ACR) criteria;<sup><xref ref-type="bibr" rid="bibr12-0961203312462265">12</xref></sup> assessment of SLE activity was based on the ECLAM index.<sup><xref ref-type="bibr" rid="bibr13-0961203312462265">13</xref></sup> All SLE patients in the study were classified as active (ECLAM &gt; 5). Baseline clinical, laboratory characteristics and treatment of active SLE patients are presented in <xref ref-type="table" rid="table1a-0961203312462265">Tables 1(a)</xref>, (<xref ref-type="table" rid="table1b-0961203312462265">b</xref>) and (<xref ref-type="table" rid="table1c-0961203312462265">c</xref>). Exclusion criteria for SLE were: the presence of CAD, a recent history suggestive of viral myocarditis, SLE-like autoimmune disorders, known congestive heart failure, pleuropericarditis, conduction defects, cardiomyopathy or endocarditis/valvular heart disease, general contraindications to CMR and presence of abnormal renal function. IM and SLE patients with low ejection fraction at the time of diagnosis were treated with angiotensin-converting enzyme (ACE) inhibitors, b-blockers and diuretics immediately after the diagnosis. Written informed consent was obtained from all patients and controls, and the local ethics committee approved the study.
<table-wrap id="table1a-0961203312462265" position="float"><label>Table 1(a)</label><caption><p>Baseline clinical characteristics of active SLE patients</p></caption>
<graphic alternate-form-of="table1a-0961203312462265" xlink:href="10.1177_0961203312462265-table1a.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Clinical characteristics</th>
<th>Mean (SD)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Disease duration (months)</td>
<td>15 (5)</td>
</tr>
<tr>
<td>Myocarditis after SLE diagnosis (months)</td>
<td>9 (2)</td>
</tr>
<tr>
<td>ECLAM</td>
<td>18 (2)</td>
</tr>
<tr>
<td>SLAM-R at diagnosis (without myoc/tis)</td>
<td>14 (7)</td>
</tr>
<tr>
<td>Patients’ global assessment, 0–10 cm</td>
<td>2.5 (2)</td>
</tr>
<tr>
<td>Physicians’ global assessment, 0–10 cm</td>
<td>3.1 (2)</td>
</tr>
<tr>
<td>SLICC Damage Index (SDI)</td>
<td>1.3 (1.2)</td>
</tr>
<tr>
<td>ACR criteria at diagnosis</td>
<td>6 (1.3)</td>
</tr>
<tr>
<td><bold>Clinical manifestations</bold></td>
<td><bold>(% of patients)</bold></td>
</tr>
<tr>
<td>Skin involvement</td>
<td>80</td>
</tr>
<tr>
<td>Musculoskeletal involvement</td>
<td>95</td>
</tr>
<tr>
<td>Pulmonary involvement</td>
<td>12</td>
</tr>
<tr>
<td>Renal involvement</td>
<td>30</td>
</tr>
<tr>
<td>Neuropsychiatric involvement</td>
<td>40</td>
</tr>
<tr>
<td>Haematological involvement</td>
<td>75</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>8</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>0</td>
</tr>
<tr>
<td>Hypertension</td>
<td>35</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203312462265"><p>SLE: systemic lupus erythematosus; SD: standard deviation; ECLAM: European Consensus Lupus Activity Measurement; SLAM-R: Systemic Lupus Activity Measure, Revised; Myoc/tis: Myocarditis; SLICC: Systemic Lupus International Collaborating Clinic; ACR: American College of Rheumatology.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table1b-0961203312462265" position="float"><label>Table 1(b)</label><caption><p>Laboratory characteristics of active SLE patients</p></caption>
<graphic alternate-form-of="table1b-0961203312462265" xlink:href="10.1177_0961203312462265-table1b.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Laboratory characteristics</th>
<th>Mean (SD)</th>
<th>Normal range</th>
</tr></thead>
<tbody align="left">
<tr>
<td>ESR (mm/h)</td>
<td>80 (5)</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Anti-dsDNA (WHO U/ml)</td>
<td>670 (10)</td>
<td>0–93</td>
</tr>
<tr>
<td>Complement 3 (mg/dl)</td>
<td>20 (5)</td>
<td>50–120</td>
</tr>
<tr>
<td>Complement 4 (mg/dl)</td>
<td>8 (3)</td>
<td>20–50</td>
</tr>
<tr>
<td>Lupus anticoagulant</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-phospholipid IgM (MPl/ml)</td>
<td>3 (1)</td>
<td>0–10</td>
</tr>
<tr>
<td>Fluorescent antinuclear antibody test (titre)</td>
<td>1: 640</td>
<td>Negative</td>
</tr>
<tr>
<td>p-anti-neutrophil antibody</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>c-anti-neutrophil antibody</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-Sjögren’s syndrome A (Ro) antibody (U/ml)</td>
<td>120 (2)</td>
<td>0–20</td>
</tr>
<tr>
<td>Anti-Sjögren’s syndrome B (La) antibody (U/ml)</td>
<td>99 (3)</td>
<td>0–20</td>
</tr>
<tr>
<td>Anti-Smith antibody (U/ml)</td>
<td>8 (2)</td>
<td>0–20</td>
</tr>
<tr>
<td>Anti-Smith/ribonucleoprotein antibody (U/ml)</td>
<td>26 (5)</td>
<td>0–20</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203312462265"><p>SLE: systemic lupus erythematosus; SD: standard deviation; ESR: erythrocyte sedimentation rate; Anti-dsDNA: anti-double-stranded DNA; WHO: World Health Organization.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table1c-0961203312462265" position="float"><label>Table 1(c)</label><caption><p>Treatment of SLE patients</p></caption>
<graphic alternate-form-of="table1c-0961203312462265" xlink:href="10.1177_0961203312462265-table1c.tif"/>
<table frame="hsides">
<tbody align="left">
<tr>
<td>Glucocorticoids (%)</td>
<td>90</td>
</tr>
<tr>
<td>Hydroxychloroquine (%)</td>
<td>10</td>
</tr>
<tr>
<td>Cyclophosphamide (%)</td>
<td>20</td>
</tr>
<tr>
<td>Azathioprine (%)</td>
<td>20</td>
</tr>
<tr>
<td>Mycophenolate mofetil (%)</td>
<td>30</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312462265"><p>SLE: systemic lupus erythematosus.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec4-0961203312462265" sec-type="methods"><title>Methods</title>
<p>In all SLE patients anti-Ro, anti-La, anti-Sm, anti-RNP, anti-double stranded DNA, lupus anticoagulant, anticardiolipin IgM, C3, C4, urinalysis and urine protein quantification were evaluated (<xref ref-type="table" rid="table1b-0961203312462265">Table 1(b)</xref>).
</p>
<p>A detailed clinical history and examination, an ECG and a routine echocardiogram were performed in all patients and controls (three to five days before the CMR evaluation). Additionally, all patients (IM and SLE) were catheterized to exclude the possibility of CAD or spasm. Clinical cardiac involvement was evaluated using the expanded criteria for diagnosis of myocarditis.<sup><xref ref-type="bibr" rid="bibr14-0961203312462265">14</xref></sup> According to these criteria, patients fulfilling two categories were considered as suspicious, three were compatible and four were considered to have a high probability of having myocarditis.<sup><xref ref-type="bibr" rid="bibr14-0961203312462265">14</xref></sup></p>
<p>The CMR study was performed five to seven days after patients’ admission to the hospital. Patients with evidence of CAD documented by coronary angiography were finally excluded from the study. Patients who had a CMR study positive for myocarditis were recommended for EMB according to guidelines.<sup><xref ref-type="bibr" rid="bibr11-0961203312462265">11</xref></sup> The investigation conforms to the principles of the Helsinki Declaration.<sup><xref ref-type="bibr" rid="bibr15-0961203312462265">15</xref></sup></p>
<p>The presence of myocarditis and left ventricular (LV) systolic function were evaluated by CMR. Myocarditis was documented using short tau inversion recovery (STIR) T2-weighted (T2-W), T1-weighted before, early after contrast media injection (EGE) and late gadolinium-enhanced images (LGE). The study was considered positive if two out three imaging sequences gave positive results.<sup><xref ref-type="bibr" rid="bibr16-0961203312462265">16</xref></sup></p>
<sec id="sec5-0961203312462265"><title>CMR evaluation of inflammation</title>
<p>Cardiovascular magnetic resonance examination was performed using a body coil in a 1.5 T Philips Intera system. STIR T2-weighted (T2-W), T1-weighted (T1-W) before, early (1 min) (EGE) and late (10–15 min) enhanced images (LGE), after contrast media injection, were evaluated in each patient. ECG-triggered, STIR T2-W multislice spin-echo sequence was performed in axial orientation and the signal ratio measured from the region of interest covering the myocardium of the left ventricle as well as within a skeletal muscle in the same slice. ECG-triggered T1-W multislice spin-echo images were also obtained in axial orientation with identical parameters before and after an intravenous bolus of 0.1 mmol/kg gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA). Measurements after Gd-DTPA were started within 1 minute of injection (EGE) in the same area as in T2-W. Immediately after the second set of T1-W images, 0.1 mmol/kg Gd-DTPA was given again and LGE images were taken 15 min later, using a three-dimensional-T1-TFE sequence, preconditioned with a 180-degree inversion pulse (flip angle = 15°, TE = 1.4 msec, TR = 5.5 ms, TI 225 to 275 ms as individually optimized to null myocardial signal, matrix 256 × 192 and slice thickness = 5 mm). Images were analysed according to previously described protocols.<sup><xref ref-type="bibr" rid="bibr6-0961203312462265">6</xref>,<xref ref-type="bibr" rid="bibr16-0961203312462265">16</xref></sup></p>
</sec>
<sec id="sec6-0961203312462265"><title>CMR functional study</title>
<p>For each subject, localizing scans were obtained to define the long (two-chamber) axis of the LV. A mid-ventricular short axis view was prescribed and used to plan a four-chamber view. The short axis orientation was then defined accurately, perpendicular to both the two- and four-chamber views. To cover the entire LV, 10 contiguous (gap = 0 mm) short axis slices were acquired in each study. The imaging sequence was a two-dimensional, multi-phase (16 cardiac phases were acquired per cardiac cycle resulting in a temporal resolution of 47 ms for a heart rate of 80 beats/min), steady-state free-precession (SSFP) sequence (TE = 1.5 ms, TR = 3.1 ms, flip angle = 70°, slice thickness = 8 mm, acquired in-plane spatial resolution = 1.8 mm × 2.0 mm) characterized by the application of balanced gradients in all directions.</p>
</sec>
<sec id="sec7-0961203312462265"><title>Image analysis</title>
<p>In T2-W STIR images the T2 ratio was derived by dividing the signal measured from the region of interest covering the LV myocardium over the signal of a skeletal muscle in the same slice.</p>
<p>In T1-W the signal enhancement was calculated by the following formula: intensity after Gd-DTPA minus the intensity before Gd-DTPA divided by the intensity before Gd-DTPA. The early myocardial enhancement (EGE) was measured from the region of interest covering the LV myocardium as well as within a skeletal muscle in the same slice. Latissimus dorsi muscle was used as an internal standard. EGE was calculated by dividing the enhancement of the myocardium by the enhancement of skeletal muscle.</p>
<p>To assess the LGE images, all short-axis slices from base to apex were inspected visually to identify areas of normal (completely nulled) myocardium. Mean signal intensity and standard deviation (SD) was derived and a threshold of &gt;2 SD exceeding the mean was used to define areas of LGE. Summing the planimetered areas of LGE in all short-axis slices yielded the total volume, which was also expressed as a proportion of total LV myocardium (% LGE). The LGE analysis was performed by one experienced reader and reviewed and confirmed by a second expert reader with both of the independent readers blinded to patient identity and clinical profile. Any discrepancies in analysis between the two readers was then adjudicated by a senior reader with &gt;10 years of CMR experience, also blinded to patient identity and clinical profile.</p>
<p>Cine images were used for the evaluation of left ventricular ejection fraction (LVEF). LV endocardial borders were outlined on the end-systolic and end-diastolic short axis view images covering the entire LV. Papillary muscles were considered myocardium. LVEF was calculated as follows: LVEF = [(volume at end-diastole − volume at end-systole)/volume at end-diastole]. MRI-MASS (Medis, Leiden, the Netherlands) software was used and the readers were blinded to the clinical data.</p>
</sec>
<sec id="sec8-0961203312462265"><title>EMB</title>
<p>In patients with CMR study positive for myocarditis who presented with reduced LVEF, recent increase in troponin with normal coronary angiogram and/or ventricular tachycardia, an EMB was performed according to guidelines of myocardial biopsy.<sup><xref ref-type="bibr" rid="bibr11-0961203312462265">11</xref></sup> Eight EMBs were obtained from the right side of the ventricular septum of each patient with clinical suspicion of myocarditis, using a flexible bioptome (Westmed, Germany) via the femoral vein approach. Four specimens were used for the histological evaluation, whereas the remaining four specimens were subjected to DNA and RNA extraction, using commercially prepared protocols, to detect viral or microbial genomes. Post-biopsy pericarditis without significant haemodynamic deterioration was developed in two IM patients.</p>
</sec>
<sec id="sec9-0961203312462265"><title>Histopathological analysis</title>
<p>EMBs were stained with Masson’s trichrome as well as Giemsa stain and examined by light microscopy.<sup><xref ref-type="bibr" rid="bibr17-0961203312462265">17</xref></sup> For immunohistological identification of cardiac immune cells, tissue sections were treated with an avidin-biotin-immunoperoxidase method according to the manufacturer’s protocol (Vectastain Elite ABC Kit, Vector Lab, Burlingame, CA, USA), applying the following monoclonal antibodies: CD3 (T cells, Novocastra Laboratories, UK) and PGM1 (macrophages, Dako, Carpinteria, CA, USA).</p>
<p>The detection of &gt;14 infiltrating leucocytes/mm<sup>2</sup> in the presence of myocyte damage and/or fibrosis in addition to enhanced human leucocyte antigen (HLA) class II expression in professional antigen-presenting immune cells and endothelium was used for the diagnosis of active myocarditis. Healing myocarditis was considered if the inflammation was less extensive (&lt;14 leucocytes/mm<sup>2</sup>), whereas healed myocarditis was characterized by multifocal fibrosis or scarring without inflammation (0 to 3 leucocytes/mm<sup>2</sup>), which is identical to normal myocardium.<sup><xref ref-type="bibr" rid="bibr17-0961203312462265">17</xref>–<xref ref-type="bibr" rid="bibr19-0961203312462265">19</xref></sup></p>
</sec>
</sec>
<sec id="sec10-0961203312462265"><title>Detection of viral genomes</title>
<p>DNA and RNA were extracted simultaneously from frozen heart muscle tissue probes. Polymerase chain reaction (PCR)/reverse transcriptase (RT)-PCR was performed for the detection of enteroviruses (EVs) (including coxsackieviruses and echoviruses), adenoviruses (ADVs), parvovirus B19 (PVB19), human cytomegalovirus, Epstein–Barr virus, herpes virus 1–6, chlamydia pneumoniae and trachomatis.<sup><xref ref-type="bibr" rid="bibr10-0961203312462265">10</xref>,<xref ref-type="bibr" rid="bibr20-0961203312462265">20</xref>–<xref ref-type="bibr" rid="bibr23-0961203312462265">23</xref></sup> The quality (purity) and quantity of the extracted nucleic acids (DNA, RNA) was evaluated on a Nanodrop 2000c spectrophotometer (ThermoScientific, Mannheim, Germany). As a control for the successful extraction of RNAs, as well as for the presence of PCR inhibitors, an RT real-time PCR assay was designed with primer/probe sequences from the glucose-6-phosphate dehydrogenase (G-6PDH) or b2-microglobulin or human acidic ribosomal protein cDNAs (data not shown). For the verification of the DNA extraction, a conventional PCR assay was designed with specific primers for the human b-globin gene (IVS-2, data not shown). During the initial application of the experiment, the specificity of the assay was ensured by checking the primers/probes sequences for possible homologies in the gene banks against all published sequences by sequence comparison analysis.</p>
<sec id="sec11-0961203312462265"><title>Statistical analysis</title>
<p>All measurements were expressed as mean ± SD. Statistical significance of the differences was investigated using the unpaired Student’s <italic>t</italic> test. Correlation between variables was sought with Pearson’s correlation coefficient. For non-parametric data, the Mann–Whitney test and Spearman’s correlation coefficient were used, respectively. Statistical significance was considered as <italic>p</italic> &lt; 0.05.</p>
</sec>
</sec>
</sec>
<sec id="sec12-0961203312462265" sec-type="results"><title>Results</title>
<p>Ten out of 50 suspected IM and five out of 25 SLE patients were excluded from the study because of CAD assessed by X-ray coronary angiography.</p>
<p>Chest pain and palpitations were the main reasons to seek medical attention for the majority of IM patients, followed by dyspnoea. In contrast, in active SLE patients only a minority presented with palpitations and chest pain. Sinus tachycardia was the main ECG finding in IM as well as SLE patients. ST elevation was identified in 10/40 IM but in none with active SLE, negative T waves in 3/40 IM and in 2/20 SLE and Q waves in 8/40 IM and in 1/20 SLE. According to expanded clinical criteria for diagnosis of myocarditis,<sup><xref ref-type="bibr" rid="bibr14-0961203312462265">14</xref></sup> 28/40 suspected IM patients and 5/20 active SLE patients were positive for myocarditis (<xref ref-type="table" rid="table2-0961203312462265">Table 2</xref>).
<table-wrap id="table2-0961203312462265" position="float"><label>Table 2</label><caption><p>Presenting symptoms and clinical findings of patients with suspected IM and active SLE. (LV dilation, regional hypertrophy and Wall motion changes were identified by CMR)</p></caption>
<graphic alternate-form-of="table2-0961203312462265" xlink:href="10.1177_0961203312462265-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>IM (<italic>n</italic> = 40)</th>
<th>SLE (<italic>n</italic> = 20)</th>
<th><italic>p</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Fatigue</td>
<td>0</td>
<td>0</td>
<td>NS</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>10</td>
<td>2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Chest pain</td>
<td>20</td>
<td>3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Palpitations</td>
<td>25</td>
<td>8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Syncope</td>
<td>0</td>
<td>0</td>
<td>NS</td>
</tr>
<tr>
<td>Viral prodrome</td>
<td>8</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fever</td>
<td>5</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ECG</td>
<td>23</td>
<td>3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Wall motion changes</td>
<td>12</td>
<td>2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LV dilation</td>
<td>10</td>
<td>2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Regional hypertrophy</td>
<td>0</td>
<td>0</td>
<td>NS</td>
</tr>
<tr>
<td>Troponine I</td>
<td>13</td>
<td>1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Clinical criteria (+) for myocarditis</td>
<td>28</td>
<td>5</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203312462265"><p>IM: infective myocarditis; SLE: systemic lupus erythematosus; LV: left ventricle; CMR: cardiac magnetic resonance imaging; ECG: electrocardiogram; NS: not significant.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Anti-SSA/Ro antibodies were positive in 18/25 and anti-phospholipid antibodies in 10/25 of active SLE patients. An increase in troponin I levels was found in 13/40 suspected IM and in 1/20 active SLE patients, with a range of 10–15 µg/l (normal values: &lt;0.1 µg/l); in NT-pro BNP in 8/40 IM and in 2/20 SLE patients, with a range of 500–900 ng/l (normal values &lt;125 ng/l); in CRP in 9/40 IM and in 18/20 SLE patients, with a range of 50–90 mg/l (normal values &lt;5 mg/l).</p>
<p>CMR was positive for myocarditis in 35/40 (87.5%) of suspected IM and in 16/20 (80%) of active SLE patients according to criteria proposed by a white paper of the Journal of the American College of Cardiology.<sup><xref ref-type="bibr" rid="bibr16-0961203312462265">16</xref></sup> T2 and EGE in IM and SLE were increased compared to controls (2.1 ± 0.54 and 2.4 ± 0.4 vs 1.6 ± 0.1 and 5.35 ± 2.3 and 5.8 ± 2 vs 3.6 ± 0.08, <italic>p</italic> &lt; 0.001, respectively). LGE, compatible with myocarditis, was identified in 28/35 IM and in only five of 16 SLE patients. LGE was located in the posterolateral wall (PS) of the LV in 20/35 and in the intraventricular septum (IVS) in 8/35 IM patients. In all SLE patients with myocarditis, the LGE was identified in the PS of LV. LGE extent was 8 ± 4.4% of myocardial mass in IM and 3.5 ± 5.5% of myocardial mass in SLE patients (<italic>p</italic> &lt; 0.001) (<xref ref-type="table" rid="table3-0961203312462265">Table 3</xref>). A positive correlation was identified only between anti-SSA/Ro antibodies and SLE myocarditis diagnosed by CMR.
<table-wrap id="table3-0961203312462265" position="float"><label>Table 3</label><caption><p>CMR measurements in patients with suspected IM, active SLE and controls</p></caption>
<graphic alternate-form-of="table3-0961203312462265" xlink:href="10.1177_0961203312462265-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>CMR parameters</th>
<th>IM (<italic>n</italic> = 40)</th>
<th>SLE (<italic>n</italic> = 20)</th>
<th>Controls (<italic>n</italic> = 20)</th>
<th><italic>p</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>T2 ratio</td>
<td>2.12 ± 0.54<sup><xref ref-type="table-fn" rid="table-fn6-0961203312462265">a</xref></sup></td>
<td>2.4 ± 0.4<sup><xref ref-type="table-fn" rid="table-fn6-0961203312462265">a</xref></sup></td>
<td>1.9 ± 0.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>EGE ratio</td>
<td>8 ± 4.4<sup><xref ref-type="table-fn" rid="table-fn6-0961203312462265">a</xref></sup></td>
<td>7.8 ± 4.8<sup><xref ref-type="table-fn" rid="table-fn6-0961203312462265">a</xref></sup></td>
<td>3.5 ± 0.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LGE (%)</td>
<td>8 ± 4.4<sup><xref ref-type="table-fn" rid="table-fn6-0961203312462265">a</xref>,<xref ref-type="table-fn" rid="table-fn7-0961203312462265">b</xref></sup></td>
<td>3.5 ± 5.5<sup><xref ref-type="table-fn" rid="table-fn6-0961203312462265">a</xref></sup></td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LVEDV (ml)</td>
<td>161.5 ± 48.9</td>
<td>146 ± 49.3</td>
<td>135 ± 15.72</td>
<td>NS</td>
</tr>
<tr>
<td>LVESV (ml)</td>
<td>78.4 ± 49.1</td>
<td>64 ± 53.8</td>
<td>54.6 ± 6.16</td>
<td>NS</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>55.3 ± 16.5</td>
<td>60.7 ± 17.2</td>
<td>62 ± 0.2</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0961203312462265"><p>CMR: cardiac magnetic resonance imaging; IM: infective myocarditis; SLE: systemic lupus erythematosus; EGE: early gadolinium-enhanced image; LGE: late gadolinium-enhanced image; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricle end-systolic volume; LVEF: left ventricular ejection fraction.</p></fn>
<fn id="table-fn6-0961203312462265"><label>a</label><p><italic>p</italic> &lt; 0.001 vs controls.</p></fn>
<fn id="table-fn7-0961203312462265"><label>b</label><p><italic>p</italic> &lt; 0.001 vs SLE.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>LVEF in the whole population of IM and SLE did not differ from that of controls (<xref ref-type="table" rid="table3-0961203312462265">Table 3</xref>). However, it was significantly decreased compared to controls in 10/35 with IM, but in only 2/16 with SLE (<italic>p</italic> &lt; 0.001). No correlation was found between T2, EGE, LGE and LVEF. Concurrent pericarditis was not identified in any of the patients.</p>
<p>EMB performed in 25/35 IM with positive CMR showed positive immunohistology in 18/25 (15 with active and three with healing myocarditis) and infectious genomes in 24/25, while in 7/16 CMR-positive SLE, a positive immunohistology was identified in 3/7 (all with active myocarditis) and an infectious genome in only 1/7. Herpes 1 and 2, Parvo B19 and CMV were the most commonly detected viral genomes in IM (Parvo B19 in 12/25, herpes 1 and 2 in 8/25 and CMV in 4/25) while CMV was detected in only one SLE patient.</p>
<p>Detailed clinical, CMR and biopsy findings of suspected IM and active SLE patients are presented in <xref ref-type="table" rid="table4-0961203312462265">Table 4</xref>. CMR images from IM and active SLE are presented in Figures <xref ref-type="fig" rid="fig1-0961203312462265">1</xref> and <xref ref-type="fig" rid="fig2-0961203312462265">2</xref>.
<fig id="fig1-0961203312462265" position="float"><label>Figure 1</label><caption><p>Cardiac magnetic resonance (CMR) images (T2, left, with evidence of high signal due to oedema and late gadolinium-enhanced image (LGE), right, with epicardial LGE in apicolateral area of left ventricle (LV)) from a patient with infective myocarditis (IM).</p></caption><graphic xlink:href="10.1177_0961203312462265-fig1.tif"/>
</fig>
<fig id="fig2-0961203312462265" position="float"><label>Figure 2</label><caption><p>Cardiac magnetic resonance (CMR) images (T2, left, with evidence of high signal due to oedema and late gadolinium-enhanced image (LGE), right, without the presence of gadolinium enhancement) from a patient with systemic lupus erythematosus (SLE).</p></caption><graphic xlink:href="10.1177_0961203312462265-fig2.tif"/>
</fig>
<table-wrap id="table4-0961203312462265" position="float"><label>Table 4</label><caption><p>Numbers of suspected IM and active SLE patients, presenting how many had coronary angiography (CA), endomyocardial biopsy, clinical diagnosis of myocarditis as well as the major CMR findings</p></caption>
<graphic alternate-form-of="table4-0961203312462265" xlink:href="10.1177_0961203312462265-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>X-ray CA</th>
<th>50</th>
<th>25</th>
<th>NS</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Diagnosed CAD</td>
<td>10/50</td>
<td>5/25</td>
<td><italic>p</italic> &lt; 0.001</td>
</tr>
<tr>
<td>Clinical criteria (+) for myocarditis</td>
<td>28/40</td>
<td>5/20</td>
<td><italic>p</italic> &lt; 0.001</td>
</tr>
<tr>
<td>CMR (+) for myocarditis</td>
<td>35/40</td>
<td>16/20</td>
<td><italic>p</italic> &lt; 0.001</td>
</tr>
<tr>
<td>T2 + EGE</td>
<td>7/35</td>
<td>11/16</td>
<td><italic>p</italic> &lt; 0.001</td>
</tr>
<tr>
<td>T2 + LGE</td>
<td>12/35</td>
<td>3/16</td>
<td><italic>p</italic> &lt; 0.001</td>
</tr>
<tr>
<td>EGE + LGE</td>
<td>16/35</td>
<td>2/16</td>
<td><italic>p</italic> &lt; 0.001</td>
</tr>
<tr>
<td>Biopsy performed</td>
<td>25/35</td>
<td>7/16</td>
<td><italic>p</italic> &lt; 0.001</td>
</tr>
<tr>
<td>Histology (+)</td>
<td>18/25</td>
<td>3/7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PCR (+)</td>
<td>24/25</td>
<td>1/7</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0961203312462265"><p>IM: infective myocarditis; SLE: systemic lupus erythematosus; CMR: cardiac magnetic resonance imaging; NS: not significant; CAD: coronary artery disease; EGE: early gadolinium-enhanced image; LGE: late gadolinium-enhanced image; PCR: polymerase chain reaction.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec13-0961203312462265" sec-type="discussion"><title>Discussion</title>
<p>In this study we evaluated the diagnostic role of CMR in detecting myocardial inflammation in SLE and its differentiation from viral myocarditis, comparing the expanded clinical criteria, the CMR and the EMB data. We found that patients with positive CMR in the setting of IM were more likely to be symptomatic than those with positive CMR during active SLE. High T2 and EGE values were the main CMR findings of IM and SLE patients. However, LGE was positive in the majority of IM, but only in the minority of SLE patients. EMB identified myocarditis in more than half of CMR-positive patients. However, PCR was positive in almost all IM, but negative in the majority of SLE patients. A positive correlation was identified between anti-SSA/Ro antibodies and SLE myocarditis diagnosed by CMR. Due to subclinical presentation of SLE myocarditis and the limitations of EMB, CMR seems to be the best alternative for assessment of myocardial inflammation during active SLE.</p>
<p>In myocarditis, independently of causative factor, local myocardial inflammation takes place at the site of injury as an effort of the immune system to eliminate the disturbing agent. This process can be induced by bacteria, viruses and/or parasites in IM.<sup><xref ref-type="bibr" rid="bibr24-0961203312462265">24</xref>,<xref ref-type="bibr" rid="bibr25-0961203312462265">25</xref></sup> The initial reaction is characterized by accumulation of leucocytes and specific serum factors at the site of injury (acute phase). If the innate defence mechanisms cannot successfully cope with the pathogenic factor, then inflammation may persist (chronic phase) and contribute to dilated cardiomyopathy.<sup><xref ref-type="bibr" rid="bibr25-0961203312462265">25</xref></sup> In SLE, immune complex mediated vascular disease results in interstitial inflammation and secondary myocyte injury.<sup><xref ref-type="bibr" rid="bibr26-0961203312462265">26</xref></sup> Circulating antibodies such as antimyocardial or anticardiolipin antibodies may also contribute to this process.<sup><xref ref-type="bibr" rid="bibr26-0961203312462265">26</xref></sup> These autoantibodies can directly affect heart tissue or, alternatively, trigger mechanisms able to cause heart damage. The consequences of autoantibodies’ damage have been reported in several heart structures such as valves, myocardium, pericardium, conduction tissue and coronary arteries in SLE, anti-phospholipid syndrome (APS), Sjögren’s syndrome and other autoimmune rheumatic diseases (ARD).<sup><xref ref-type="bibr" rid="bibr26-0961203312462265">26</xref></sup> The clinical presentation of SLE myocarditis ranges from 3% to 15%, although it is more common in autopsy studies, suggesting the largely subclinical presentation of the disease.<sup><xref ref-type="bibr" rid="bibr26-0961203312462265">26</xref></sup> Some reports support an association between anti-SSA/Ro antibodies and myocarditis.<sup><xref ref-type="bibr" rid="bibr26-0961203312462265">26</xref></sup> SLE myocarditis should be treated immediately with high-dose steroids to avoid early and/or late complications.</p>
<p>The clinical presentation of IM and SLE myocarditis may be similar and could progress to ventricular dysfunction, dilated cardiomyopathy (DCM) and heart failure. Recently, CMR has been proposed as the best non-invasive technique for diagnosis of myocarditis.<sup><xref ref-type="bibr" rid="bibr16-0961203312462265">16</xref></sup> However, to our knowledge, there are no studies evaluating the diagnostic role of CMR in the detection of myocardial inflammation in SLE and its differentiation from viral myocarditis. In our study, using the expanded clinical criteria and performing CMR and EMB in a population of active SLE and suspected IM patients, we identified that although the clinical diagnosis was of high probability in the majority of IM patients, SLE myocarditis was mainly subclinical.</p>
<p>CMR is inherently very attractive for the detection of myocarditis because of its sensitivity in detecting tissue changes taking place during inflammation. T2 is increased during inflammation or necrosis because of the development of oedema. Data comparing the T2 values with myocardial biopsy are rather rare.<sup><xref ref-type="bibr" rid="bibr10-0961203312462265">10</xref>,<xref ref-type="bibr" rid="bibr27-0961203312462265">27</xref></sup> In our patients, T2 values did not correlate with the EMB results nor with the LVEF values in IM and SLE patients as we documented in our previous studies.<sup><xref ref-type="bibr" rid="bibr10-0961203312462265">10</xref></sup> Previous studies of SLE myocarditis demonstrated an increase of myocardial T1<sup>26</sup> and T2 relaxation time.<sup><xref ref-type="bibr" rid="bibr27-0961203312462265">27</xref></sup> According to these studies, T1 calculated from magnetic resonance imaging (MRI) is often abnormal in SLE and probably indicates myocardial involvement.<sup><xref ref-type="bibr" rid="bibr26-0961203312462265">26</xref></sup> Additionally, the increase in T2 relaxation is a sensitive indicator of myocardial disease in active SLE, even in the absence of myocardial involvement by clinical criteria.<sup><xref ref-type="bibr" rid="bibr27-0961203312462265">27</xref></sup> Since it is well known that free water protons exhibit such a pattern in myocarditis, oedema was considered as the pathophysiological mechanism behind this phenomenon. This finding has also been documented by myocardium histopathological evaluation in SLE myocarditis.<sup><xref ref-type="bibr" rid="bibr28-0961203312462265">28</xref></sup> The detection of oedema in our patients was in agreement with previous studies in SLE myocarditis.<sup><xref ref-type="bibr" rid="bibr6-0961203312462265">6</xref>,<xref ref-type="bibr" rid="bibr7-0961203312462265">7</xref>,<xref ref-type="bibr" rid="bibr26-0961203312462265">26</xref>–<xref ref-type="bibr" rid="bibr28-0961203312462265">28</xref></sup></p>
<p>EGE reflects increased capillary leakage, and LGE is indicative of myocardial fibrosis, according to the previous experience from both infective and SLE myocarditis.<sup><xref ref-type="bibr" rid="bibr7-0961203312462265">7</xref>,<xref ref-type="bibr" rid="bibr16-0961203312462265">16</xref>,<xref ref-type="bibr" rid="bibr27-0961203312462265">27</xref>–<xref ref-type="bibr" rid="bibr29-0961203312462265">29</xref></sup> However, studies with both EGE and LGE in SLE myocarditis are rather limited in the literature.<sup><xref ref-type="bibr" rid="bibr7-0961203312462265">7</xref>,<xref ref-type="bibr" rid="bibr27-0961203312462265">27</xref>,<xref ref-type="bibr" rid="bibr29-0961203312462265">29</xref></sup> Our results were in agreement with these studies, documenting their important role in the CMR detection of SLE myocarditis.<sup><xref ref-type="bibr" rid="bibr7-0961203312462265">7</xref>,<xref ref-type="bibr" rid="bibr27-0961203312462265">27</xref></sup> Furthermore, we also assessed that positive LGE was not the dominant finding, at least at the early stages of SLE myocarditis, as in our patients. Our findings about LGE were in agreement with those of Edwards et al., who also did not identify LGE areas during the course of SLE myocarditis.<sup><xref ref-type="bibr" rid="bibr30-0961203312462265">30</xref></sup></p>
<p>The presence of decreased LVEF, documented in 10/35 with IM and in 2/16 with SLE, is another interesting finding. The high percentage of IM, with decreased LVEF in our IM suspected patients, may be due to the fact that, as a tertiary cardiac centre, we accept the most complicated cases. On the other hand, the low percentage of decreased LVEF in active SLE was expected because usually only a small percentage of SLE myocarditis presents clinically with low LVEF.<sup><xref ref-type="bibr" rid="bibr26-0961203312462265">26</xref></sup></p>
<p>In EMB, a positive histology was identified in 72% of IM, but only in 42.6% of SLE patients. Our data were in agreement with previous studies, finding that the sensitivity of EMB even after the application of immunohistological techniques remains low.<sup><xref ref-type="bibr" rid="bibr31-0961203312462265">31</xref></sup> According to some studies, the histological evaluation of myocardial specimens yields diagnosis in only 10–20% of cases.<sup><xref ref-type="bibr" rid="bibr32-0961203312462265">32</xref></sup> Although biopsy provides crucial information regarding the type of inflammatory infiltrates (lymphocytic, neutrophilic, eosinophilic, granulomatous and giant cell), the sampling error still remains a serious limitation.<sup><xref ref-type="bibr" rid="bibr31-0961203312462265">31</xref></sup> It is also important to note that only four to six biopsy samples are routinely performed, and a careful post-mortem analysis of proven myocarditis cases demonstrated that &gt;17 samples were necessary to correctly diagnose myocarditis in &gt;80% of cases.<sup><xref ref-type="bibr" rid="bibr33-0961203312462265">33</xref>,<xref ref-type="bibr" rid="bibr34-0961203312462265">34</xref></sup> Recently, the cardioscope-guided biopsy has been successfully used to increase the accuracy of histological diagnosis.<sup><xref ref-type="bibr" rid="bibr35-0961203312462265">35</xref></sup> Additionally, EMB is of value to identify different types of myocarditis before starting specific anti-inflammatory treatment.<sup><xref ref-type="bibr" rid="bibr36-0961203312462265">36</xref></sup> However, it is an invasive technique and cannot be routinely used for patient follow-up.</p>
<p>According to previous studies, the definite diagnosis of lupus myocarditis is histological, with typical features being interstitial oedema, focal necrosis/fibrosis, and focal or diffuse inflammatory cellular infiltrates.<sup><xref ref-type="bibr" rid="bibr37-0961203312462265">37</xref></sup> However, despite being the gold standard for diagnosis, EMB cannot be used routinely or repeatedly, particularly in asymptomatic patients. CMR is sensitive to many of the changes that characterize lupus myocarditis and can be used as a non-invasive alternative in these cases.<sup><xref ref-type="bibr" rid="bibr38-0961203312462265">38</xref></sup></p>
<p>Infectious genomes were identified in the majority of IM patients, and herpes 1 and 2, Parvo B19 and CMV were the most commonly detected viral genomes. Our results in IM were in agreement with previous studies<sup><xref ref-type="bibr" rid="bibr7-0961203312462265">7</xref>,<xref ref-type="bibr" rid="bibr10-0961203312462265">10</xref>,<xref ref-type="bibr" rid="bibr17-0961203312462265">17</xref>,<xref ref-type="bibr" rid="bibr29-0961203312462265">29</xref></sup> indicating the high frequency of these viruses in the myocardium. Furthermore, the addition of PCR techniques can offer important information. However, a positive PCR by itself is not obligatory proof of myocarditis because viral genomes without positive histology have already been identified in otherwise healthy people.<sup><xref ref-type="bibr" rid="bibr3-0961203312462265">3</xref></sup> Different infectious agents can be innocent bystanders in myocardium and only under special conditions, such as immune defects, can they contribute to clinically overt myocarditis. A combination of a CMR approach and PCR evaluation of myocardial specimens seems to be more sensitive for the diagnosis of myocarditis than the currently used gold standard of myocardial histology.<sup><xref ref-type="bibr" rid="bibr17-0961203312462265">17</xref></sup> Interestingly, CMV was also identified in the myocardial specimens of one SLE patient. There are in the literature some sporadic cases referring to CMV myocarditis in SLE.<sup><xref ref-type="bibr" rid="bibr29-0961203312462265">29</xref>,<xref ref-type="bibr" rid="bibr39-0961203312462265">39</xref>–<xref ref-type="bibr" rid="bibr43-0961203312462265">43</xref></sup> However, in all of them the clinical presentation was dramatic, with rapid LV deterioration. In contrast, our SLE patient had mild symptomatology, positive CMR and negative immunohistology of myocardial specimens. Under these circumstances, we may assume that CMV was not involved in the aetiology of myocarditis, but it was in the myocardium because of a previous subclinical infection, unnoticed by the patient.</p>
<p>The current study presents several limitations: a) lack of a true gold standard for myocarditis detection because of sampling error of biopsy; b) small patient number and small biopsy number, especially in SLE; c) lack of targeted biopsy in the area of LGE because of higher number of complications; d) lack of biopsy in controls (ethical reasons); e) lack of T2 and T1 mapping for quantification of oedema and diffuse, interstitial fibrosis; f) possible referral bias because, as a tertiary centre, we admit the most severe cases; g) catheterization laboratory referral bias because all subjects were catheterized presumably because of clinical indications; h) biopsy referral bias because biopsy was performed only on patients who fulfilled the criteria given by guidelines about myocardial biopsy;<sup><xref ref-type="bibr" rid="bibr11-0961203312462265">11</xref></sup> i) lack of short- and long-term follow-up; and j) lack of CMR evaluation in completely asymptomatic active SLE in order to identify the possibility of clinically silent lupus myocarditis.</p>
<sec id="sec14-0961203312462265"><title>Clinical implications of our findings</title>
<p>Our findings may have some important clinical implications in the diagnosis of myocarditis. Although an overt clinical presentation contributes to a definite diagnosis in the majority of IM patients, a positive CMR can strengthen the diagnosis in clinically uncertain cases. In contrast, active SLE patients with atypical cardiac involvement may have a CMR positive for myocarditis although they are under immunosuppressive treatment and considered as being under control. The diagnosis of SLE myocarditis may suggest a different therapeutic approach and application of more cardio-specific immunosuppressive treatment. At the moment it is unknown if subclinical SLE myocarditis should be treated as aggressively as the clinically overt kind. Furthermore, there are no data about the possible evolution of subclinical myocarditis to heart failure, as it is observed in IM.<sup><xref ref-type="bibr" rid="bibr10-0961203312462265">10</xref>,<xref ref-type="bibr" rid="bibr44-0961203312462265">44</xref>,<xref ref-type="bibr" rid="bibr45-0961203312462265">45</xref></sup> Results coming from a recent study indicated that ethnicity and disease activity at diagnosis were associated with the occurrence of myocarditis in SLE and also that myocarditis did not significantly affect disease activity over time, but has some impact on damage accrual and survival, reflecting overall the more severe disease in these SLE patients.<sup><xref ref-type="bibr" rid="bibr46-0961203312462265">46</xref></sup> Further multicentre studies with short- and long-term follow-up are needed before we will be able to present final statements.</p>
<p>In conclusion, after evaluation of the diagnostic role of CMR in a population of suspected IM and active SLE patients, we proved that high T2 and EGE values were the main characteristics of IM and SLE patients. LGE was positive in the majority of IM patients and only in the minority of active SLE patients. EMB identified myocarditis in more than half of CMR-positive patients. However, PCR was positive in almost all IM, but unusual in SLE. Due to subclinical presentation of SLE myocarditis and the limitations of EMB, CMR seems to be the best alternative for assessment of myocardial inflammation during active SLE.</p>
</sec>
</sec>
</body>
<back>
<sec id="sec15-0961203312462265"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec16-0961203312462265"><title>Conflict of interest statement</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312462265"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dec</surname><given-names>GW Jr</given-names></name><name><surname>Palacios</surname><given-names>IF</given-names></name><name><surname>Fallon</surname><given-names>JT</given-names></name><etal/></person-group>. <article-title>Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome</article-title>. <source>N Engl J Med</source> <year>1985</year>; <volume>312</volume>: <fpage>885</fpage>–<lpage>890</lpage>.</citation></ref>
<ref id="bibr2-0961203312462265"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dec</surname><given-names>GW Jr</given-names></name><name><surname>Waldman</surname><given-names>H</given-names></name><name><surname>Southern</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Viral myocarditis mimicking acute myocardial infarction</article-title>. <source>J Am Coll Cardiol</source> <year>1992</year>; <volume>20</volume>: <fpage>85</fpage>–<lpage>89</lpage>.</citation></ref>
<ref id="bibr3-0961203312462265"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dennert</surname><given-names>R</given-names></name><name><surname>Crijns</surname><given-names>HJ</given-names></name><name><surname>Heymams</surname><given-names>S</given-names></name></person-group>. <article-title>Acute viral myocarditis</article-title>. <source>Eur Heart J</source> <year>2008</year>; <volume>29</volume>: <fpage>2073</fpage>–<lpage>2082</lpage>.</citation></ref>
<ref id="bibr4-0961203312462265"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baboonian</surname><given-names>C</given-names></name><name><surname>Treasure</surname><given-names>T</given-names></name></person-group>. <article-title>Meta-analysis of the association of enteroviruses with human heart disease</article-title>. <source>Heart</source> <year>1999</year>; <volume>78</volume>: <fpage>539</fpage>–<lpage>543</lpage>.</citation></ref>
<ref id="bibr5-0961203312462265"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pauschinger</surname><given-names>M</given-names></name><name><surname>Bowles</surname><given-names>NE</given-names></name><name><surname>Fuentes-Garcia</surname><given-names>FJ</given-names></name><etal/></person-group>. <article-title>Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction</article-title>. <source>Circulation</source> <year>1999</year>; <volume>99</volume>: <fpage>1348</fpage>–<lpage>1354</lpage>.</citation></ref>
<ref id="bibr6-0961203312462265"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tincani</surname><given-names>A</given-names></name><name><surname>Rebaioli</surname><given-names>CB</given-names></name><name><surname>Taglietti</surname><given-names>M</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus</article-title>. <source>Rheumatology (Oxford)</source> <year>2006</year>; <volume>45</volume>(<issue>Supplement 4</issue>): <fpage>iv8</fpage>–<lpage>iv13</lpage>.</citation></ref>
<ref id="bibr7-0961203312462265"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Aty</surname><given-names>H</given-names></name><name><surname>Boyé</surname><given-names>P</given-names></name><name><surname>Zagrosek</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: Comparison of different approaches</article-title>. <source>J Am Coll Cardiol</source> <year>2005</year>; <volume>45</volume>: <fpage>1815</fpage>–<lpage>1822</lpage>.</citation></ref>
<ref id="bibr8-0961203312462265"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruder</surname><given-names>O</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Nothnagel</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>EuroCMR (European Cardiovascular Magnetic Resonance) registry: Results of the German pilot phase</article-title>. <source>J Am Coll Cardiol</source> <year>2009</year>; <volume>54</volume>: <fpage>1457</fpage>–<lpage>1466</lpage>.</citation></ref>
<ref id="bibr9-0961203312462265"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahrholdt</surname><given-names>H</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Deluigi</surname><given-names>CC</given-names></name><etal/></person-group>. <article-title>Presentation, patterns of myocardial damage and clinical course of viral myocarditis</article-title>. <source>Circulation</source> <year>2006</year>; <volume>114</volume>: <fpage>1581</fpage>–<lpage>1590</lpage>.</citation></ref>
<ref id="bibr10-0961203312462265"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mavrogeni</surname><given-names>S</given-names></name><name><surname>Spargias</surname><given-names>C</given-names></name><name><surname>Bratis</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Myocarditis as a precipitating factor for heart failure: Evaluation and 1-year follow-up using cardiovascular magnetic resonance and endomyocardial biopsy</article-title>. <source>Eur J Heart Fail</source> <year>2011</year>; <volume>13</volume>: <fpage>830</fpage>–<lpage>837</lpage>.</citation></ref>
<ref id="bibr11-0961203312462265"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>LT</given-names></name><name><surname>Baughman</surname><given-names>KL</given-names></name><name><surname>Feldman</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology</article-title>. <source>Circulation</source> <year>2007</year>; <volume>116</volume>: <fpage>2216</fpage>–<lpage>2233</lpage>.</citation></ref>
<ref id="bibr12-0961203312462265"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>AS</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>The 1982 revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>1271</fpage>–<lpage>1277</lpage>.</citation></ref>
<ref id="bibr13-0961203312462265"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vitali</surname><given-names>C</given-names></name><name><surname>Bencivelli</surname><given-names>W</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE</article-title>. <source>Clin Exp Rheumatol</source> <year>1992</year>; <volume>10</volume>: <fpage>541</fpage>–<lpage>547</lpage>.</citation></ref>
<ref id="bibr14-0961203312462265"><label>14</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>PP</given-names></name><name><surname>Schultheiss</surname><given-names>HP</given-names></name><name><surname>Myocarditis</surname></name></person-group>. In: <person-group person-group-type="editor"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Mann</surname><given-names>DL</given-names></name><etal/></person-group> (eds), <source>Braunwald’s heart disease. A textbook for cardiovascular medicine</source>, <edition>8th ed</edition>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Saunders Elsevier</publisher-name>, p. <fpage>1775</fpage>–<lpage>1792</lpage>.</citation></ref>
<ref id="bibr15-0961203312462265"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rickham</surname><given-names>PP</given-names></name></person-group>. <article-title>Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki</article-title>. <source>Br Med J</source> <year>1964</year>; <volume>2</volume>: <fpage>177</fpage>–<lpage>177</lpage>.</citation></ref>
<ref id="bibr16-0961203312462265"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedrich</surname><given-names>M</given-names></name><name><surname>Sechtem</surname><given-names>U</given-names></name><name><surname>Schulz-Menger</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Cardiovascular magnetic resonance in myocarditis: A JACC white paper</article-title>. <source>J Am Coll Cardiol</source> <year>2009</year>; <volume>53</volume>: <fpage>1475</fpage>–<lpage>1487</lpage>.</citation></ref>
<ref id="bibr17-0961203312462265"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahrholdt</surname><given-names>H</given-names></name><name><surname>Goedecke</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Cardiovascular magnetic resonance assessment of human myocarditis. A comparison to histology and molecular pathology</article-title>. <source>Circulation</source> <year>2004</year>; <volume>109</volume>: <fpage>1250</fpage>–<lpage>1258</lpage>.</citation></ref>
<ref id="bibr18-0961203312462265"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aretz</surname><given-names>HT</given-names></name><name><surname>Billingham</surname><given-names>ME</given-names></name><name><surname>Edwards</surname><given-names>WD</given-names></name><etal/></person-group>. <article-title>Myocarditis: A histopathologic definition and classification</article-title>. <source>Am J Cardiovasc Pathol</source> <year>1987</year>; <volume>1</volume>: <fpage>3</fpage>–<lpage>14</lpage>.</citation></ref>
<ref id="bibr19-0961203312462265"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>JC</given-names></name><name><surname>Hilliard</surname><given-names>AA</given-names></name><name><surname>Cooper</surname><given-names>LT Jr</given-names></name><name><surname>Rihal</surname><given-names>CS</given-names></name></person-group>. <article-title>Diagnosis and treatment of viral myocarditis</article-title>. <source>Mayo Clin Proc</source> <year>2009</year>; <volume>84</volume>: <fpage>1001</fpage>–<lpage>1009</lpage>.</citation></ref>
<ref id="bibr20-0961203312462265"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>G</given-names></name><name><surname>Santoro</surname><given-names>F</given-names></name><name><surname>Vaglia</surname><given-names>F</given-names></name><name><surname>Gobbi</surname><given-names>A</given-names></name><name><surname>Lusso</surname><given-names>P</given-names></name><name><surname>Malnati</surname><given-names>MS</given-names></name></person-group>. <article-title>Real-time quantitative PCR for human herpesvirus 6 DNA</article-title>. <source>J Clin Microb</source> <year>2000</year>; <volume>38</volume>: <fpage>4042</fpage>–<lpage>4048</lpage>.</citation></ref>
<ref id="bibr21-0961203312462265"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>JC</given-names></name><name><surname>Ehlers</surname><given-names>MM</given-names></name><name><surname>Grabow</surname><given-names>W</given-names></name></person-group>. <article-title>Detection of enteroviruses in treated drinking water</article-title>. <source>Water Research</source> <year>2004</year>; <volume>38</volume>: <fpage>2699</fpage>–<lpage>2705</lpage>.</citation></ref>
<ref id="bibr22-0961203312462265"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuan</surname><given-names>M</given-names></name></person-group>. <article-title>Detection and rapid differentiation of human enteroviruses following genomic amplification</article-title>. <source>J Clin Microb</source> <year>1997</year>; <volume>35</volume>: <fpage>2598</fpage>–<lpage>2601</lpage>.</citation></ref>
<ref id="bibr23-0961203312462265"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mavrogeni</surname><given-names>S</given-names></name><name><surname>Manoussakis</surname><given-names>M</given-names></name><name><surname>Spargias</surname><given-names>K</given-names></name><name><surname>Kolovou</surname><given-names>G</given-names></name><name><surname>Saroglou</surname><given-names>G</given-names></name><name><surname>Cokkinos</surname><given-names>DV</given-names></name></person-group>. <article-title>Myocardial involvement in a patient with chlamydia trachomatis infection</article-title>. <source>J Card Fail</source> <year>2008</year>; <volume>14</volume>: <fpage>351</fpage>–<lpage>353</lpage>.</citation></ref>
<ref id="bibr24-0961203312462265"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedrich</surname><given-names>MG</given-names></name><name><surname>Strohm</surname><given-names>O</given-names></name><name><surname>Schultz-Menger</surname><given-names>J</given-names></name><name><surname>Marciniak</surname><given-names>H</given-names></name><name><surname>Luft</surname><given-names>FC</given-names></name><name><surname>Dietz</surname><given-names>R</given-names></name></person-group>. <article-title>Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis</article-title>. <source>Circulation</source> <year>1998</year>; <volume>97</volume>: <fpage>1802</fpage>–<lpage>1809</lpage>.</citation></ref>
<ref id="bibr25-0961203312462265"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>PP</given-names></name><name><surname>Mason</surname><given-names>JW</given-names></name></person-group>. <article-title>Advances in the understanding of myocarditis</article-title>. <source>Circulation</source> <year>2001</year>; <volume>104</volume>: <fpage>1076</fpage>–<lpage>1082</lpage>.</citation></ref>
<ref id="bibr26-0961203312462265"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>JA</given-names></name><name><surname>Woodard</surname><given-names>PK</given-names></name><name><surname>Dávila-Román</surname><given-names>VG</given-names></name><etal/></person-group>. <article-title>Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: A preliminary report</article-title>. <source>Lupus</source> <year>2005</year>; <volume>14</volume>: <fpage>137</fpage>–<lpage>144</lpage>.</citation></ref>
<ref id="bibr27-0961203312462265"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Been</surname><given-names>M</given-names></name><name><surname>Thomson</surname><given-names>BJ</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Myocardial involvement in systemic lupus erythematosus detected by magnetic resonance imaging</article-title>. <source>Eur Heart J</source> <year>1988</year>; <volume>9</volume>: <fpage>1250</fpage>–<lpage>1256</lpage>.</citation></ref>
<ref id="bibr28-0961203312462265"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Sutani</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Immunohistochemical study of the endo-myocardial biopsy of systemic lupus erythematosus</article-title>. <source>J Cardiol</source> <year>1995</year>; <volume>25</volume>: <fpage>181</fpage>–<lpage>188</lpage>.</citation></ref>
<ref id="bibr29-0961203312462265"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mavrogeni</surname><given-names>S</given-names></name><name><surname>Spargias</surname><given-names>K</given-names></name><name><surname>Markussis</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Myocardial inflammation in autoimmune diseases: Investigation by cardiovascular magnetic resonance and endomyocardial biopsy</article-title>. <source>Inflamm Allergy Drug Targets</source> <year>2009</year>; <volume>8</volume>: <fpage>390</fpage>–<lpage>397</lpage>.</citation></ref>
<ref id="bibr30-0961203312462265"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>NC</given-names></name><name><surname>Ferro</surname><given-names>CJ</given-names></name><name><surname>Townend</surname><given-names>JN</given-names></name><name><surname>Steeds</surname><given-names>RP</given-names></name></person-group>. <article-title>Myocardial disease in systemic vasculitis and autoimmune disease detected by cardiovascular magnetic resonance</article-title>. <source>Rheumatology (Oxford)</source> <year>2007</year>; <volume>46</volume>: <fpage>1208</fpage>–<lpage>1209</lpage>.</citation></ref>
<ref id="bibr31-0961203312462265"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahrholdt</surname><given-names>H</given-names></name><name><surname>Goedecke</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Cardiovascular magnetic resonance assessment of human myocarditis. A comparison to histology and molecular pathology</article-title>. <source>Circulation</source> <year>2004</year>; <volume>109</volume>: <fpage>1250</fpage>–<lpage>1258</lpage>.</citation></ref>
<ref id="bibr32-0961203312462265"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>EB</given-names></name><name><surname>Hutchins</surname><given-names>GM</given-names></name><name><surname>Herskowitz</surname><given-names>A</given-names></name><name><surname>Rose</surname><given-names>NR</given-names></name><name><surname>Baughaman</surname><given-names>KL</given-names></name></person-group>. <article-title>Clinicopathologic description of myocarditis</article-title>. <source>J Am Coll Cardiol</source> <year>1991</year>; <volume>18</volume>: <fpage>1617</fpage>–<lpage>1618</lpage>.</citation></ref>
<ref id="bibr33-0961203312462265"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karatolios</surname><given-names>K</given-names></name><name><surname>Pankuweit</surname><given-names>S</given-names></name><name><surname>Maisch</surname><given-names>B</given-names></name></person-group>. <article-title>Diagnosis and treatment of myocarditis: The role of endomyocardial biopsy</article-title>. <source>Curr Treat Options Cardiovasc Med</source> <year>2007</year>; <volume>9</volume>: <fpage>473</fpage>–<lpage>481</lpage>.</citation></ref>
<ref id="bibr34-0961203312462265"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hauck</surname><given-names>AJ</given-names></name><name><surname>Kearney</surname><given-names>DL</given-names></name><name><surname>Edwards</surname><given-names>WD</given-names></name></person-group>. <article-title>Evaluation of post-mortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: Implications for the role of sampling error</article-title>. <source>Mayo Clin Proc</source> <year>1989</year>; <volume>64</volume>: <fpage>1235</fpage>–<lpage>1245</lpage>.</citation></ref>
<ref id="bibr35-0961203312462265"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heymans</surname><given-names>S</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><etal/></person-group>. <article-title>Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology</article-title>. <source>Eur J Heart Fail</source> <year>2009</year>; <volume>11</volume>: <fpage>119</fpage>–<lpage>129</lpage>.</citation></ref>
<ref id="bibr36-0961203312462265"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Relationship between cardioscopic images and histological changes in the left ventricle of patients with idiopathic myocarditis</article-title>. <source>Eur J Heart Fail</source> <year>2011</year>; <volume>13</volume>: <fpage>504</fpage>–<lpage>512</lpage>.</citation></ref>
<ref id="bibr37-0961203312462265"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wijetunga</surname><given-names>M</given-names></name><name><surname>Rockson</surname><given-names>S</given-names></name></person-group>. <article-title>Myocarditis in systemic lupus erythematosus</article-title>. <source>Am J Med</source> <year>2002</year>; <volume>113</volume>: <fpage>419</fpage>–<lpage>423</lpage>.</citation></ref>
<ref id="bibr38-0961203312462265"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mavrogeni</surname><given-names>S</given-names></name><name><surname>Vassilopoulos</surname><given-names>D</given-names></name></person-group>. <article-title>Is there a place for cardiovascular magnetic resonance imaging in the evaluation of cardiovascular involvement in rheumatic diseases?</article-title> <source>Semin Arthritis Rheum</source> <year>2011</year>; <volume>41</volume>: <fpage>488</fpage>–<lpage>496</lpage>.</citation></ref>
<ref id="bibr39-0961203312462265"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hachfi</surname><given-names>W</given-names></name><name><surname>Laurichesse</surname><given-names>JJ</given-names></name><name><surname>Chauveheid</surname><given-names>MP</given-names></name><etal/></person-group>. <article-title>Acute cytomegalovirus infection revealing systemic lupus erythematosus [in French]</article-title>. <source>Rev Med Interne</source> <year>2011</year>; <volume>32</volume>: <fpage>e6</fpage>–<lpage>e8</lpage>.</citation></ref>
<ref id="bibr40-0961203312462265"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Declerck</surname><given-names>L</given-names></name><name><surname>Queyrel</surname><given-names>V</given-names></name><name><surname>Morell-Dubois</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Cytomegalovirus and systemic lupus: Severe infection and difficult diagnosis [in French]</article-title>. <source>Rev Med Interne</source> <year>2009</year>; <volume>30</volume>: <fpage>789</fpage>–<lpage>793</lpage>.</citation></ref>
<ref id="bibr41-0961203312462265"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baumgratz</surname><given-names>JF</given-names></name><name><surname>Vila</surname><given-names>JH</given-names></name><name><surname>Silva</surname><given-names>JP</given-names></name><name><surname>Fonseca</surname><given-names>L</given-names></name><name><surname>Rodrigues</surname><given-names>EA</given-names></name><name><surname>Knobel</surname><given-names>E</given-names></name></person-group>. <article-title>Cardiogenic shock due to cytomegalovirus myocarditis: Successful clinical treatment</article-title>. <source>Rev Bras Cir Cardiovasc</source> <year>2010</year>; <volume>25</volume>: <fpage>149</fpage>–<lpage>153</lpage>.</citation></ref>
<ref id="bibr42-0961203312462265"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roubille</surname><given-names>C</given-names></name><name><surname>Brunel</surname><given-names>AS</given-names></name><name><surname>Gahide</surname><given-names>G</given-names></name><name><surname>Vernhet Kovacsik</surname><given-names>H</given-names></name><name><surname>Le Quellec</surname><given-names>A</given-names></name></person-group>. <article-title>Cytomegalovirus (CMV) and acute myocarditis in an immunocompetent patient</article-title>. <source>Intern Med</source> <year>2010</year>; <volume>49</volume>: <fpage>131</fpage>–<lpage>133</lpage>.</citation></ref>
<ref id="bibr43-0961203312462265"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernández-Ruiz</surname><given-names>M</given-names></name><name><surname>Muñoz-Codoceo</surname><given-names>C</given-names></name><name><surname>López-Medrano</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: Successful treatment with oral valganciclovir</article-title>. <source>Intern Med</source> <year>2008</year>; <volume>47</volume>: <fpage>1963</fpage>–<lpage>1966</lpage>.</citation></ref>
<ref id="bibr44-0961203312462265"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agüero</surname><given-names>J</given-names></name><name><surname>Navarro</surname><given-names>J</given-names></name><name><surname>Medina</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>Clinical variables associated with the presence of inflammatory infiltrates in patients with dilated cardiomyopathy undergoing heart transplantation</article-title>. <source>Transplant Proc</source> <year>2008</year>; <volume>40</volume>: <fpage>3017</fpage>–<lpage>3019</lpage>.</citation></ref>
<ref id="bibr45-0961203312462265"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frustaci</surname><given-names>A</given-names></name><name><surname>Russo</surname><given-names>MA</given-names></name><name><surname>Chimenti</surname><given-names>C</given-names></name></person-group>. <article-title>Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: The TIMIC study</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>1995</fpage>–<lpage>2002</lpage>.</citation></ref>
<ref id="bibr46-0961203312462265"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Apte</surname><given-names>M</given-names></name><name><surname>McGwin</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Vilá</surname><given-names>LM</given-names></name><etal/></person-group>. <article-title>Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort (LV)</article-title>. <source>Rheumatology (Oxford)</source> <year>2008</year>; <volume>47</volume>: <fpage>362</fpage>–<lpage>367</lpage>.</citation></ref>
</ref-list>
</back>
</article>